Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn:
”Major Bleeding With Apixaban vs Aspirin
A Subanalysis of the ARTESiA Randomized Clinical Trial
Question In patients with subclinical atrial fibrillation (SCAF) treated with apixaban or aspirin, what are the sites, severity, and factors associated with major bleeding?
Findings In this subanalysis of the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial including 3961 patients, although the rate of major gastrointestinal bleeding was higher with apixaban compared with aspirin, critical site, intracranial bleeding, and fatal bleeding were similar between arms.
Most major bleeding events in both groups were characterized by decreased hemoglobin and were not emergencies.
Meaning This study found that in patients with SCAF, apixaban increased major gastrointestinal bleeding compared with aspirin but intracranial and fatal bleeding events were similar between groups; most bleeding events were nonemergencies characterized by a decrease in hemoglobin.
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial | Bleeding and Transfusion | JAMA Cardiology | JAMA Network”
Read the full article here.
Article: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
Authors: Deborah M. Siegal, Christian Sticherling, Jeff S. Healey, William F. McIntyre, Lene S. Christensen, Ratika Parkash, Thomas Vanassche, David Conen, Michael Gold, Christopher B. Granger, Jens Cosedis Nielsen, Marc Carrier, Daniel M. Wojdyla, Julia W. Erath, Lena Rivard, Valentina Kutyifa, David J. Wright, Renato D. Lopes
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 21, 2026, 01:57A New Approach to Understanding Plasmin Generation and Fibrinolysis – RPTH Journal
-
Jul 21, 2026, 01:52Maria Diaz Alonso: Delivering My First International Oral Presentation at ISTH 2026
-
Jul 21, 2026, 01:44Megan Preece: Presenting New Research on Antiphospholipid Syndrome at ISTH 2026
-
Jul 21, 2026, 01:28Dhamirah Nazihah Mohd Nasiruddin: A Milestone in My Haemostasis and Thrombosis Journey at ISTH 2026
-
Jul 21, 2026, 00:55Anita Brikman on PPTA’s First-Half 2026 Achievements
-
Jul 21, 2026, 00:50Caitlin Raymond: Can Therapeutic Plasma Exchange Reduce Microplastics?
-
Jul 21, 2026, 00:46Yohei Hisada: Science, Collaboration, and New Beginnings at ISTH 2026
-
Jul 21, 2026, 00:41Ahmed Koriesh: Inside Our 2026 Stroke Simulation Lab
-
Jul 20, 2026, 21:17Connie Montgomery: Building Community Through the HFA Black Voices Summit